Global, regional, and national burdens of leukemia from 1990 to 2017: a systematic analysis of the global burden of disease 2017 study

Abstract

We described the spatial and temporal trends of the annual leukemia incidence, prevalence, mortality, and disability-adjusted life years (DALYs) from 1990 to 2017. Leukemia case numbers and age-standardized rates (ASRs) were extracted from the Global Burden of Disease (GBD) study 2017. The estimated annual percentage change (EAPC) in the ASR was calculated using a generalized linear model with a Gaussian distribution. The risk factors for death and DALYs due to leukemia were estimated within the comparative risk assessment framework of the GBD study. Globally, the prevalence, age-standardized prevalence rate (ASPR), and EAPC in leukemia cases in 2017 were 2.43 (95% uncertainty interval (UI) 2.19 to 2.59) million, 32.26 (95% UI 29.02 to 34.61), and 0.22% (95% CI 0.13 to 0.31, P<0.01), respectively, during 1990-2017. The trends of the age-standardized incidence, deaths, and DALY rate all significantly decreased globally. The burden of leukemia was higher in males than in female. An increasing leukemia burden was found in high-middle-sociodemographic index (SDI) countries and territories. The burden of leukemia tended to be lower in high-SDI regions than that in lower SDI regions. The rapid increases in the prevalent cases and prevalence rate of leukemia is urgent to be solved in the future.

The Global Burden of Leukemia and Its Attributable Factors in 204 Countries and Territories: Findings from the Global Burden of Disease 2019 Study and Projections to 2030

“…Based on the GBD study and previous GBD reports [ 22 – 25 ], we used a 5-year interval to explore the age distribution of the four leukemia subtypes and assess age-specific potential risk factors contributing to leukemia-related deaths and DALYs.…”

Trends in Disease Burden of Chronic Lymphocytic Leukemia at the Global, Regional, and National Levels From 1990 to 2019, and Projections Until 2030: A Population-Based Epidemiologic Study

“…Data were available for 204 countries/territories, including China, India, and France. The methodologies of the overall GBD 2019 and estimations of disease burden were as described in the previous studies ( 15 , 16 , 19 ).…”

“…The Global Burden of Disease (GBD) study launched by the Global Burden of Disease Collaborative Network assesses 286 causes of death, 369 diseases and injuries, and 87 risk factors in 204 countries and territories (13). Several studies have used GBD data to estimate the disease burden of leukemia (14)(15)(16), but none of them focused on CLL. In addition, studies predicting the disease burden of CLL based on GBD study results are scarce.…”

The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019

“…In addition, significant differences of disease burden patterns were existed in heterogeneous types of leukemias. Previously, most studies using the Global Burden of Disease (GBD) platform focused on the entire leukemia category, leading to a neglect of the specific internal genetic differences existing across leukemia [ 16 , 17 ]. Thus, there is no guarantee that the evidence offered by these studies could provide accurate guidance on targeting CLL burden management.…”